Skip to main content

Advertisement

SpringerLink
Log in

Primary central nervous system lymphoma: essential points in diagnosis and management

  • Review Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Primary central nervous system lymphoma (PCNSL) is an extra-nodal non-Hodgkin lymphoma. PCNSL is defined as lymphoma involving the brain, leptomeninges, eyes, or spinal cord without evidence of lymphoma outside the CNS. Treatment includes induction with chemotherapy and consolidation with whole-brain radiotherapy or high-dose chemotherapy supported by autologous stem cell transplantation. High-dose methotrexate is the most important drug in cases with PCNSL, and this drug will be used in combination with small molecules, BTK inhibitors, new monoclonal antibodies, and checkpoint blockers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Batchelor TT, Thye LS, Habermann TM. Current management concepts: primary central nervous system lymphoma, natural killer T-cell lymphoma nasal type, and post-transplant lymphoproliferative disorder. Am Soc Oncol Educ Book. 2016;35:e354–66.

    Article  Google Scholar 

  2. Bathla G, Hegde A. Lymphomatous involvement of the central nervous system. Clin Radiol. 2016;71:602–9.

    Article  CAS  PubMed  Google Scholar 

  3. Haldorsen IS, Espeland A, Larsson EM. Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJR Am J Roentgenol. 2011;32:984–92.

    CAS  Google Scholar 

  4. van der Sanden GA, Schouten LJ, van Dijck JA, van der Andel JP, van der Maazen RW, Coebergh JW, Working Group of Specialists in Neuro-Oncology in the Southern and Eastern Netherlands. Primary central nervous system lymphomas: incidence and survival in the Southern and Eastern Netherlands. Cancer. 2002;94:1548–56.

    Article  PubMed  Google Scholar 

  5. Deckert M, Engert A, Brück W, Ferreri AJ, Finke J, Illerhaus G, Klapper W, Korfel A, Küppers R, Maarouf M, Montesinos-Rongen M, Paulus W, Schlegel U, Lassmann H, Wiestler OD, Siebert R, DeAngelis LM. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia. 2011;25:1797–807.

    Article  CAS  PubMed  Google Scholar 

  6. Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105:1414–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Montserrat E. Primary CNS lymphoma: in search of the evidence. Lancet Haematol. 2015;2:227–8.

    Article  Google Scholar 

  8. Ruiz A, Post MJ, Bundschu C, Ganz WI, Georgiou M. Primary central nervous system lymphoma in patients with AIDS. Neuroimaging Clin N Am. 1997;7:281–96.

    CAS  PubMed  Google Scholar 

  9. Phan TG, O’Neill BP, Kurtin PJ. Posttransplant primary central nervous system lymphoma. Neuro Oncol. 2000;2:229–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Zhang D, Hu LB, Henning T, Ravarani EM, Zou LG, Feng XY, Wang WX, Wen L. MRI findings of primary CNS lymphoma in 26 immunocompetent patients. Korean J Radiol. 2010;11:269–77.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4:222–30.

    Article  PubMed  Google Scholar 

  12. Erdag N, Bhorade RM, Alberico RA, Yousuf N, Patel MR. Primary lymphoma of the central nervous system: typical and atypical CT and MRI imaging appearances. AJR Am J Roentgenol. 2001;176:1319–26.

    Article  CAS  PubMed  Google Scholar 

  13. Thurnher MM, Rieger A, Kleibl-Popov C, Settinek U, Henk C, Haberler C, Schindler E. Primary central nervous system lymphoma in AIDS: a wider spectrum of CT and MRI findings. Neuroradiology. 2001;43:29–35.

    Article  CAS  PubMed  Google Scholar 

  14. Fraser E, Gruenberg K, Rubenstein JL. New approaches in primary central nervous system lymphoma. Chin Clin Oncol. 2015;11:2304–3865.

    Google Scholar 

  15. Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A. Rituximab, methotrexate, procarbazine and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long term outcome. J Clin Oncol. 2013;31:3971–9.

    Article  CAS  PubMed  Google Scholar 

  16. Chapuy B, Roemer MGM, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden EA, Sun HH, Homer H, Aono M, Pinkus GS, Ligon AH, Ligon KL, Ferry JA, Freeman GJ, van Hummelen P, Golub TR, Getz G, Rodig S, de Jong D, Monti S, Shipp MA. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127:869–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Fischer L, Korfel A, Pfeiffer S, Kiewe P, Volk HD, Cakiroglu H, Widmann T, Thiel E. CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res. 2009;15:5968–73.

    Article  CAS  PubMed  Google Scholar 

  18. Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, Rosenbaum JT. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood. 2003;101:815–21.

    Article  CAS  PubMed  Google Scholar 

  19. Smith JR, Falkenhagen KM, Coupland SE, Chipps TJ, Rosenbaum JT, Braziel RM. Malignant B cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1. Am J Clin Pathol. 2007;127:633–41.

    Article  CAS  PubMed  Google Scholar 

  20. Sung CO, Kim SC, Karnan S, Karube K, Shin HJ, Nam DH, Suh YL, Kim SH, Kim JY, Kim SJ, Kim WS, Seto M, Ko YH. Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. Blood. 2011;117:1291–300.

    Article  CAS  PubMed  Google Scholar 

  21. Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol. 2008;26:96–105.

    Article  CAS  PubMed  Google Scholar 

  22. Sasayama T, Nakamizo S, Nishihara M, Kawamura A, Tanaka H, Mizukawa K, Miyake S, Taniguchi M, Hosoda K, Kohmura E. Cerebrospinal fluid interleukin-10 is a potentially useful biomerker in immunocompetent primary central nervous system lymphoma (PCNSL). Neuro Oncol. 2012;14:368–80.

    Article  CAS  PubMed  Google Scholar 

  23. Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Karch J, Okada C, Hyun W, Parikh S, Haqq C, Shuman M. Gene expression and angiotropism in primary CNS lymphoma. Blood. 2006;107:3716–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470:115–9.

    Article  CAS  PubMed  Google Scholar 

  25. Montesinos-Rongen M, Godlewaka E, Brunn A, Wiestler OD, Siebert R, Deckert M. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol. 2011;122:791–2.

    Article  PubMed  Google Scholar 

  26. Gonzalez-Aguilar A, Idbaih A, Boissellier B, Habbita N, Rosetto M, Laurenge A, Bruno A, Jouvet A, Polivka M, Adam C, Figarella-Branger D, Miquel C, Vital A, Ghesquieres H, Gressin R, Delwail V, Taillandier L, Chinot O, Soubeyran P, Gyan E, Choquet S, Houllier C, Soussain C, Tanguy ML, Marie Y, Mokhtari K, Hoang-Xuan K. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res. 2012;18:5203–11.

    Article  CAS  PubMed  Google Scholar 

  27. Kraan W, Horlings HM, van Keimpema M, Schilder-Tol EJ, Oud ME, Scheepstra C, Kluin PM, Kersten MJ, Spaargaren M, Pals ST. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large Bcell lymphomas presenting at immune-privileged sites. Blood Cancer J. 2013;3:e139.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Braggio E, Van Wier S, Ojha J, McPhail E, Asmann YW, Egn J, da Silva JA, Schiff D, Lopes MB, Decker PA, Valdez R, Tibes R, Eckloff B, Witzig TE, Stewart AK, Fonseca R, O’Neill BP. Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas. Clin Cancer Res. 2015;2013(21):3986–94.

    Article  CAS  Google Scholar 

  29. Hattori K, Sakata-Yanagimoto M, Okoshi Y, Goshima Y, Yanagimoto S, Nakamoto-Matsubara R, Sato T, Noguchi M, Takano S, Ishikawa E, Yamamoto T, Matsumura A, Chiba S. MYD88 (L265P) mutation is associated with an unfavorable outcome of primary central nervous system lymphoma. Br J Haematol. 2016;. doi:10.1111/bjh.14080 (Epub ahead of print).

    PubMed  Google Scholar 

  30. Yamada S, Ishida Y, Matsuno A, Yamazaki K. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. Leuk Lymphoma. 2015;56:2141–5.

    Article  CAS  PubMed  Google Scholar 

  31. Todorovic Balint M, Jelicic J, Mihaljevic B, Kostic J, Stanic B, Balint B, Pejanovic N, Lucic B, Tosic N, Marjanovic I, Stojiljkovic M, Karan-Djurasevic T, Perisic O, Rakocevic G, Popovic M, Raicevic S, Bila J, Antic D, Andjelic B, Pavlovic S. Gene mutation profiles in primary diffuse large B cell lymphoma of central nervous system: next generation sequencing analyses. Int J Mol Sci. 2016;. doi:10.3390/ijms17050683.

    PubMed  PubMed Central  Google Scholar 

  32. Camilleri-Broet S, Criniere E, Broet P, Delwail V, Mokhtari K, Moreau A, Kujas M, Raphaël M, Iraqi W, Sautès-Fridman C, Colombat P, Hoang-Xuan K, Martin A. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006;107:190–6.

    Article  CAS  PubMed  Google Scholar 

  33. Tang YZ, Booth TC, Bhogal P, Malhotra A, Wilhelm T. Imaging of primary central nervous system lymphoma. Clin Radiol. 2011;66:768–77.

    Article  CAS  PubMed  Google Scholar 

  34. Partovi S, Karimi S, Lyo JK, Esmaeili A, Tan J, Deangelis LM. Multimodality imaging of primary CNS lymphoma in immunocompetent patients. Br J Radiol. 1036;2014(87):20130684. doi:10.1259/bjr.20130684.

    Google Scholar 

  35. Swerdlow SH, Campo TC, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.

    Article  CAS  PubMed  Google Scholar 

  36. Mooney KL, Choy W, Woodard J, Xian RR, Deal TM, Kendle RF, Said J, Grody W, Yang I. Primary central nervous system gama-delta cytotoxic T-cell lymphoma. Case Rep J Clin Neurosci. 2016;26:138–40.

    Article  Google Scholar 

  37. Lu JQ, O’Kelly C, Girgis S, Emery D, Power C, Blevins G. Neuroinflammation preceding and accompanying primary central nervous system lymphoma: case study and literature review. World Neurosurg. 2015;88:e1–8.

    Google Scholar 

  38. Ponzoni M, Berger F, Chassagne-Clement C, Tinguely M, Jouvet A, Ferreri AJ, Dell’Oro S, Terreni MR, Doglioni C, Weis J, Cerati M, Milani M, Iuzzolino P, Motta T, Carbone A, Pedrinis E, Sanchez J, Blay JY, Reni M, Conconi A, Bertoni F, Zucca E, Cavalli F, Borisch B, International Extranodal Lymphoma Study Group. Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas. Br J Haematol. 2007;138:16–23.

    Article  Google Scholar 

  39. Josephson SA, Papanastassiou AM, Berger MS, Barbaro NM, McDermott MW, Hilton JF, Miller BL, Geschwind MD. The diagnostic utility of brain biopsy procedures in patients with rapidly deteriorating neurological conditions or dementia. J Neurosurg. 2007;106:72–5.

    Article  PubMed  Google Scholar 

  40. Fischer L, Martus P, Weller M, Klasen HA, Rohden B, Röth A, Storek B, Hummel M, Nägele T, Thiel E, Korfel A. Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology. 2008;71:1102–8.

    Article  CAS  PubMed  Google Scholar 

  41. Chan CC, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, Cassoux N, Touitou V, Smith JR, Batchelor TT, Pulido JS. Primary vitreoretinal lymphoma: a report from an international Primary Central Nervous System Lymphoma Collaborative Group Symposium. Oncologist. 2011;16:1589–99.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Slone HW, Blake JJ, Shah R. CT and MRI findings of intracranial lymphoma. AJR Am J Roentgenol. 2005;184:1679–85.

    Article  PubMed  Google Scholar 

  43. Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O’Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F, International Primary CNS Lymphoma Collaborative Group. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034–43.

    Article  PubMed  Google Scholar 

  44. Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J, Frenay M, De Beule N, Delattre JY, Baron B. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol. 2003;21:2726–31.

    Article  CAS  PubMed  Google Scholar 

  45. Rubenstein JL, Wong VS, Kadoch C, Gao HX, Barajas R, Chen L, Josephson SA, Scott B, Douglas V, Maiti M, Kaplan LD, Treseler PA, Cha S, Hwang JH, Cinque P, Cyster JG, Lowell C. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood. 2013;121:4740–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M, Gold R, Maghnouj A, Zöllner H, Reinacher-Schick A, Schmiegel W, Hahn SA, Schroers R. Identification of microRNAs in the cerebrospinal fluid marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011;117:3140–6.

    Article  CAS  PubMed  Google Scholar 

  47. Nguyen-Them L, Costopoulos M, Tanguy ML, Houillier C, Choquet S, Benanni H, Elias-Shamieh R, Armand M, Faivre G, Glaisner S, Malak S, Vargaftig J, Hoang-Xuan K, Ahle G, Touitou V, Cassoux N, Davi F, Merle-Béral H, Le Garff-Tavernier M, Soussain C, French LOC. Network forCNS Lymphoma. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment responsive patients. Eur J Cancer. 2016;61:69–76.

    Article  CAS  PubMed  Google Scholar 

  48. Mercadel S, Cortes-Romera M, Velez P, Climent F, Gamez C, Gonzalez-Barca E. Positron emission tomography combined with computed tomography in the initial evaluation and response assessment in primary central nervous system lymphoma. Med Clin (Barc). 2015;144:503–6.

    Article  Google Scholar 

  49. Doolittle ND, Korfel A, Lubow MA. Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology. 2013;81:84–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Dong YH, Teng ZJ, Hu M, Chen YM, Zhao HF, Zhang SQ, Lyu PY. Primary central nervous system lymphoma. Chin Med J. 2016;129:609–11.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Küker W, Nagele T, Korfel A, Heckl S, Thiel E, Bamberg M, Weller M, Herrlinger U. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol. 2005;71:169–77.

    Article  Google Scholar 

  52. Coulon A, Lafitte F, Hoang-Xuan K, Martin-Duverneuil N, Mokhtari K, Blustajn J, Chiras J. Radiographic findings in 37 cases of primary CNS lymphoma in immunocompetent patients. Eur Radiol. 2002;12:329–40.

    Article  CAS  PubMed  Google Scholar 

  53. Adachi K, Yamaguchi F, Node Y, Kobayashi S, Takagi R, Teramoto A. Neuroimaging of primary central nervous system lymphoma in immunocompetent patients: comparison of recent and previous findings. J Nippon Med Sch. 2013;80:174–83.

    Article  CAS  PubMed  Google Scholar 

  54. Yap KK, Sutherland T, Liew E, Tartaglia CJ, Pang M, Trost N. Magnetic resonance features of primary central nervous system lymphoma in the immunocompetent patient: a pictorial essay. J Med Imaging Radiat Oncol. 2012;56(2):179–86.

    Article  PubMed  Google Scholar 

  55. Iwamoto FM, DeAngelis LM, Abrey LE. Primary dural lymphomas: a clinicopathologic study of treatment and outcome in eight patients. Neurology. 2006;66:1763–5.

    Article  PubMed  Google Scholar 

  56. Taylor JW, Flanagan EP, O’Neill BP, Siegal T, Omuro A, Deangelis L, Baehring J, Nishikawa R, Pinto F, Chamberlain M, Hoang-Xuan K, Gonzalez-Aguilar A, Batchelor T, Blay JY, Korfel A, Betensky RA, Lopes MB, Schiff D. Primary leptomeningeal lymphoma: International Primary CNS Lymphoma Collaborative Group report. Neurology. 2013;81:1690–6.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Raz E, Tinelli E, Antonelli M, Canevelli M, Fiorelli M, Bozzao L, Di Piero V, Caramia F. MRI findings in lymphomatosis cerebri: description of a case and revision of the literature. J Neuroimaging. 2011;21:183–6.

    Article  Google Scholar 

  58. Williams RL, Meltzer CC, Smirniotopoulos JG, Fukui MB, Inman M. Cerebral MR imaging in intravascular lymphomatosis. AJNR Am J Neuroradiol. 1998;19:427–31.

    CAS  PubMed  Google Scholar 

  59. Jimenez de la Pena MM, Vincente LG, Alanso RC, Cabero SF, Suarez AM. The multiple faces of nervous system lymphoma. Atypical MRI features and contribution of the advanced imaging. Curr Probl Diagn Radiol. 2016;. doi:10.1067/j.cpradiol.

    Google Scholar 

  60. Kuker W, Herrllinger U, Gronewaller E, Rohrbach JM, Weller M. Ocular manifestations of primary nervous system lymphoma: what can be expected from imaging? J Neurol. 2002;249:1713–6.

    Article  CAS  PubMed  Google Scholar 

  61. Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell’Oro S, Zucca E, Cavalli F. Prognostic scoring system for primary CNS lymphomas: the international Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21:266–72.

    Article  PubMed  Google Scholar 

  62. Cho H, Chang JH, Kim YR, Kim SJ, Chung H, Park H, Lee YL, Jang JE, Kim Y, Kim SH, Yang WI, Suh CO, Cheong JW, Min JW, Kim JS. The role of upfront autologous stem cell transplantation in high-risk younger patients with primary central nervous system lymphoma. Br J Haematol. 2016;174:444–53.

    Article  CAS  PubMed  Google Scholar 

  63. Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, DeAngelis LM. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24:5711–5.

    Article  PubMed  Google Scholar 

  64. Jang JE, Kim YR, Kim SJ, Cho H, Chung H, Lee JY, Park H, Kim Y, Cheong JW, Min YH, Kim JS. A new prognostic model using absolute lymphocyte count in patients with primary central nervous systemlymphoma. Eur J Cancer. 2016;57:127–35.

    Article  PubMed  Google Scholar 

  65. Vitolo U, Seymour JF, Martelli M, Illerhaus G, Illıdge T, Zucca E, Campo E, Ladetto M. ESMO Guidelines Committee. Ann Oncol. 2016;. doi:10.1093/annonc/mdcw175.

    Google Scholar 

  66. Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Deckert M, Fimmers R, Helmstaedter C, Atasoy A, Klockgether T, Schlegel U. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21:4489–95.

    Article  CAS  PubMed  Google Scholar 

  67. Korfel A, Thiel E, Martus P, Mohle R, Griesinger F, Rauch M, Roth A, Hertenstein B, Fischer T, Hundsberger T, Mergenthaler HG, Junghaunss C, Birnhaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Weller M. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology. 2015;84:1242–8.

    Article  CAS  PubMed  Google Scholar 

  68. Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, Cheson BD, Kaplan LD. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31:3061–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Munch-Peterson HD, Asmar F, Dimopoulos K, Areskevuciute A, Brown P, Girkov MS, Pederson A, Sjö LD, Heegard S, Broholm H, Kristensen LS, Ralfikar E, Grenbaek K. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy. Acta Neuropathol Commun. 2016;22(4):40. doi:10.1186/s40478-016-0307-6.

    Article  Google Scholar 

  70. Schwindt H, Vater I, Kreuz M, Montesinos-Rongen M, Brunn A, Richter J, Gesk S, Ammerpohl O, Wiestler OD, Hasenclever D, Deckert M, Siebert R. Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma. Leukemia. 2009;23:1875–84.

    Article  CAS  PubMed  Google Scholar 

  71. Philips EH, Fox ChP, Cwynarski K. Primary CNS lymphomas. Curr Hematol Malig Rep. 2013;9:243–53.

    Article  Google Scholar 

  72. Rubenstein JL, Gupta NK, Mannis GN, LaMarre AK, Treseler P. How I treat CNS lymphomas. Blood. 2013;122:2318–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Roth P, Hoang-Xuan K. Challenges in the treatment of elderly patients with primary central nervous system lymphoma. Curr Opin Neurol. 2014;27:697–701.

    Article  CAS  PubMed  Google Scholar 

  74. Mathew BS, Carson KA, Grossman SA. Initial response to glucocorticoids. Cancer. 2006;106:383–7.

    Article  PubMed  CAS  Google Scholar 

  75. Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F, International Extranodal Lymphoma Study Group (IELSG). High dose cytarabine plus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374:1512–20.

    Article  CAS  PubMed  Google Scholar 

  76. Thiel E, Korfel A, Marthus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M. High dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11:1036–47.

    Article  CAS  PubMed  Google Scholar 

  77. Omuro AM, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Huchet A, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Touitou V, Barrié M, del Rio MS, Gonzalez-Aguilar A, Houillier C, Delgadillo D, Lacomblez L, Tanguy ML, Hoang-Xuan K. Methotrexate and temozolamide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in elderly population: an intergroup ANOCEF-GOELAMS randomizsed phase 2 trial. Lancet Haematol. 2015;2:e251–9.

    Article  PubMed  Google Scholar 

  78. Qian L, Zhou C, Shen J, Cen J, Yin W. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy. Oncotarget. 2016;. doi:10.18632/oncotarget.8370 (Epub ahead of print).

    Google Scholar 

  79. Glantz MJ, Cole BF, Recht L. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol. 1998;16:1561–7.

    Article  CAS  PubMed  Google Scholar 

  80. Schorb E, Finke J, Ferreri AJ, Ihorst G, Mikesch K, Kasenda B, Fritsch K, Fricker H, Burger E, Grishina O, Valk E, Zucca E, Illerhaus G. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma-a randomized phase III trial (MATRix). BMC Cancer. 2016;21(16):282. doi:10.1186/s12885-016-2311-4.

    Article  Google Scholar 

  81. Shan GD, Yahalom J, Correra DD. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007;25:4730–5.

    Article  CAS  Google Scholar 

  82. Bellinzona M, Roser F, Ostertag H, Gaab RM, Saini M. Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases. Eur J Surg Oncol. 2005;31:100–5.

    Article  CAS  PubMed  Google Scholar 

  83. Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM. Intensive methotrexate and cytarabine followed by hig-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003;21:4151–6.

    Article  CAS  PubMed  Google Scholar 

  84. Blay JY, Conroy T, Chevreau C, Thyss A, Quesnel N, Eghbali H, Bouabdallah R, Coiffier B, Wagner JP, Le Mevel A, Dramais-Marcel D, Baumelou E, Chauvin F, Biron P. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol. 1998;16:864–71.

    Article  CAS  PubMed  Google Scholar 

  85. Xu WQ, Zhang LY, Chen XY, Pan BH, Mao JQ, Song H, Li JY, Tang YM. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies. Cancer Chemother Pharmacol. 2014;73:79–86.

    Article  CAS  PubMed  Google Scholar 

  86. Green JM. Glucarpidase to combat toxic levels of methotrexate in patients. Ther Clin Risk Manag. 2012;8:403–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Ferreri AJ, Dell’Oro S, Foppoli M, Bernardi M, Brandes AA, Tosoni A, Montanari M, Balzarotti M, Spina M, Ilariucci F, Zaja F, Stelitano C, Bobbio F, Corazzelli G, Baldini L, Ponzoni M, Picozzi P, Caligaris Cappio F, Reni M. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology. 2006;66:1435–8.

    Article  CAS  PubMed  Google Scholar 

  88. Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006;24:3865–70.

    Article  CAS  PubMed  Google Scholar 

  89. Illerhaus G, Muller F, Feuerhake F, Schafer AO, Ostertag C, Finke J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first- line treatment for primary lymphoma of the central nervous system. Haematologica. 2008;93:147–8.

    Article  CAS  PubMed  Google Scholar 

  90. Juergens A, Pels H, Rogowski S, Fliessbach K, Glasmacher A, Engert A, Reiser M, Diehl V, Vogt-Schaden M, Egerer G, Schackert G, Reichmann H, Kroschinsky F, Bode U, Herrlinger U, Linnebank M, Deckert M, Fimmers R, Schmidt-Wolf IG, Schlegel U. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol. 2010;67:182–9.

    Article  CAS  PubMed  Google Scholar 

  91. Ferreri AJ, Guerra E, Regazzi M, Pasini F, Ambrosetti A, Pivnik A, Gubkin A, Calderoni A, Spina M, Brandes A, Ferrarese F, Rognone A, Govi S, Dell’Oro S, Locatelli M, Villa E, Reni M. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer. 2004;90:353–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Batchelor TT, Carson K, O’Neill A, Grossman SA, Alavi J, New P, Hochberg F, Priet R. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-7. J Clin Oncol. 2003;21:1044–149.

    Article  CAS  PubMed  Google Scholar 

  93. Rubenstein JL, Chen L, Advani R, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, Cha S, Shuman MA, Damon LE. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013;121:745–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Ekenel M, Iwamoto FM, Ben-Porat LS, Panageas KS, Yahalom J, DeAngelis LM, Abrey LE. Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy. Cancer. 2008;113:1025–31.

    Article  CAS  PubMed  Google Scholar 

  95. Birnbaum T, Stadler EA, von Baumgarten L, Straube A. Rituximab significantly improves complete response rate in patients with primary CNS lymphoma. J Neurooncol. 2012;109:285–91.

    Article  CAS  PubMed  Google Scholar 

  96. Khan RB, Shi W, Thaler HT. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol. 2002;58:175–8.

    Article  PubMed  Google Scholar 

  97. Sandor V, Stark-Vancs V, Pearson D, Nussenblat R, Whitcup SM, Brouwers P, Patronas N, Heiss J, Jaffe E, deSmet M, Kohler D, Simon R, Wittes R. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol. 1998;16:3000–6.

    Article  CAS  PubMed  Google Scholar 

  98. Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman MA. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003;101:466–8.

    Article  CAS  PubMed  Google Scholar 

  99. Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab mono-therapy for patients with recurrent primary CNS lymphoma. Neurology. 2011;76:929–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Holdhoff M, Ambady P, Abdelaziz A. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014;83:235–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Mocikova H, Pytlik R, Sykorova A, Janikova A, Prochazka V, Vokurka S, Berkova A. Belada D, Campr V, Buresova L, Trneny M; Czech Lymphoma Study Group. Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry. Leuk Lymphoma. 2016;18:1–7.

    Google Scholar 

  102. Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A,Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F33, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG) for the International Extranodal Study Group (IELSG). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016; 3:e217–7.

  103. Gregory G, Arumugaswamy A, Leung T, Chan KL, Abikhair M, Tam C, Bajel A, Cher L, Grigg A, Ritchie D, Opat S. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. Neuro Oncol. 2013;15:1068–173.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Kansara R, Shenkier TN, Connors JM, Sehn LH, Savage KJ, Gerrie AS, Villa D. Rituximab with high-dose methotrexate in primary central nervous system lymphoma. Am J Hematol. 2015;90:1149–54.

    Article  CAS  PubMed  Google Scholar 

  105. Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, Issa S, Damon L, Prados M, McDermott M, O’Brien J, Haqq C, Shuman M. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007;25:1350–6.

    Article  CAS  PubMed  Google Scholar 

  106. Ferreri AJM, Illerhaus G. The role of autologous stem cell transplantation in primary central nervous system lymphoma. Treating this malignancy. Blood. 2016;127:1642–9.

    Article  CAS  PubMed  Google Scholar 

  107. Correra DD, Maron L, Harder H, Klein M, Armstrong CL, Calabrese P, Bromberg JE, Abrey LE, Batchelor TT, Schiff D. Cognitive functions in primary central nervoussystem lymphoma: literaturereview and assessmentguidelines. Ann Oncol. 2007;18:1145–51.

    Article  Google Scholar 

  108. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ, Radiation Therapy Oncology Group Study. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002;20:4643–8.

    Article  PubMed  Google Scholar 

  109. Ponzoni M, Issa S, Batchelor TT, Rubenstein JL. Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma. Ann Oncol. 2014;25:316–22.

    Article  CAS  PubMed  Google Scholar 

  110. Motomura K, Natsume A, Fuji M, Ito M, Wakabayashi T. Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy. Leuk Lymphoma. 2011;52:2069–75.

    Article  CAS  PubMed  Google Scholar 

  111. Schiff D, Hong F, Alexander B. Defining optimal initial therapyprimary CNS lymphoma. Lancet Haematol. 2016;3:e206–7.

    Article  PubMed  Google Scholar 

  112. Wiebe VJ, Smith BR, DeGregorio MW, Rappaport JM. Pharmacology of agents used in bone marrow transplant conditioning regimens. Crit Rev Oncol Hematol. 1992;13:241–70.

    Article  CAS  PubMed  Google Scholar 

  113. Illerhaus G, Fritsch K., Egerer G. Sequential high dose immunochemotherapy followed by autologous stem cell transplantation for patients with primary central nervous system lymphoma—a multicenter study by the Collaborative PCNSL Study Group Freiburg. Blood. 2012; 120 (abstr 302).

  114. Illerhaus G, Kasenda B, Ihorst G, Egerer G, Lamprecht M, Keller U, Wolf HH, Hirt C, Stilgebauer S, Binder M, Hau P, Edinger M, Frickhofen N, Robert MB, Möhle R, Roth A, Pfreundschuh M, van Baumgarten L, Deckert M, Hader H, Valk E, Schorb E, Fritsch K, Finke J. High dose chemotherapy with autologous stem cell transplantation for newly diagnosed primary CNS lymphoma: a pospective, single arm, phase 2 trial. Lancet Haematol. 2016;3:e388–97.

    Article  PubMed  Google Scholar 

  115. Hohaus S. High-dose therapy for primary CNS lymphoma. Lancet Haematol. 2016;3:e359–60.

    Article  PubMed  Google Scholar 

  116. Lai R, Rosenblum MK, DeAngelis LM. Primary CNS lymphoma: a whole-brain disease? Neurology. 2002;59:1557–62.

    Article  PubMed  Google Scholar 

  117. Blay JY, Bouhour D, Carrie C, Bouffet E, Brunat-Mentigny M, Philip T, Biron P. The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin’s lymphoma of patients with no known cause of immunosuppression. Blood. 1995;86:2922–9.

    CAS  PubMed  Google Scholar 

  118. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, Van’t Veer M, Hansen M, Soubeyran P, Taphoorn M, Thomas J, Van den Bent M, Fickers M, Van Imhoff G, Rozewicz C, Teodorovic I, van Glabbeke M, European Organization for Research and Treatment of Cancer Lymphoma Group. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Gropu Phase II Trial 20962. J Clin Oncol. 2003;21:4483–8.

    Article  CAS  PubMed  Google Scholar 

  119. Iwabuchi M, Shibamoto Y, Sugie C, Ayakawa S, Ogino H, Baba F. Partial-brain radiotherapy for primary central nervous system lymphoma: mult-institutional experience. J Radiat Res. 2015;57:164–8.

    Article  PubMed  PubMed Central  Google Scholar 

  120. Neuwelt EA, Goldman DL, Dahlborg SA, Crossen J, Ramsey F, Roman-Goldstein S, Braziel R, Dana B. Primary CNS lymphoma treated with osmotic blood-brain disruption: prolonged survival and preservation of cognitive function. J Clin Oncol. 1991;9:1580–90.

    Article  CAS  PubMed  Google Scholar 

  121. McAllister LD, Doolittle ND, Guastadisegni PE, Kraemer DF, Lacy CA, Crossen JR, Neuwelt EA. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery. 2000;46:51–60.

    Article  CAS  PubMed  Google Scholar 

  122. Pels H, Juergens A, Schirgens I, Glasmacher A, Schulz H, Engert A, Schackert G, Reichmann H, Bode U, Deckert M, Fimmers R, Urbach H, Schmidt-Wolf IG, Schlegel U. Early response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma. Neuro-Oncology. 2010;12:720–4.

    Article  PubMed  PubMed Central  Google Scholar 

  123. Jacomet C, Girard PM, Lebrette MG, Farese VL, Monfort L, Rozenbaum W. Intravenous methotrexate for primary central nervous system non-Hodgkin’s lymphoma in AIDS. AIDS. 1997;11:1725–30.

    Article  CAS  PubMed  Google Scholar 

  124. Fritsch K, Kasenda B, Hader C, Nikkhah G, Prinz M, Haug V, Haug S, Ihorst G, Finke J, Illerhaus G. Immunochemotherapy with rituximab, methotrexate, procarbazine and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol. 2011;22:2080–5.

    Article  CAS  PubMed  Google Scholar 

  125. Ghesquieres H, Ferlay C, Sebban C, Perol D, Bosly A, Casasnovas O, Reman O, Coiffier B, Tilly H, Morel P, Van den Neste E, Colin P, Haioun C, Biron P, Blay JY. Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Ann Oncol. 2010;21:842–50.

    Article  CAS  PubMed  Google Scholar 

  126. Illerhaus G, Marks R, Muller F, Ihorst G, Feuerhake F, Deckert M, Ostertag C, Finke J. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol. 2009;20:319–25.

    Article  CAS  PubMed  Google Scholar 

  127. Jahnke K, Korfel A, Martus P, Weller M, Herrlinger U, Schmittel A, Fischer L, THiel A, German Primary Central Nervous System Lymphoma Study Group (G-PCNSL-SG). High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol. 2005;16:445–9.

    Article  CAS  PubMed  Google Scholar 

  128. Ferreri AJ. How I treat primary CNS lymphoma. Blood. 2011;118:510–22.

    Article  CAS  PubMed  Google Scholar 

  129. Korfel A, Elter T, Thiel E, Hänel M, Möhle R, Schroers R, Reiser M, Dreyling M, Eucker J, Scholz C, Metzner B, Röth A, Birkmann J, Schlegel U, Martus P, Illerhaus G, Fischer L. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica. 2013;98:364–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Cote GM, Hochberg EP, Muzikansky A, Hochberg FH, Drappatz J, McAfee SL, Batchelor TT, LaCasce AS, Fisher DC, Abramson JS, Armand P, Chen YB. Autologous stem cell transplantation with thiotepa, busulfan and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2012;18:76–83.

    Article  CAS  PubMed  Google Scholar 

  131. Falzetti F, Di Ianni M, Ballanti S, Iodice G, Reale A, Minelli O, Serio G, Martelli MF, Dammacco F, Vacca A, Ria R. High döşe thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma. Clin Exp Med. 2012;12:165–71.

    Article  CAS  PubMed  Google Scholar 

  132. Alvarnas JC, Negrin RS, Horning SJ, Hu WW, Long GD, Schriber JR, Stockerl-Goldstein K, Tierney K, Wong R, Blume KG, Chao NJ. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2000;6:52–8.

    Article  Google Scholar 

  133. Nayak L, Abrey LE, Drappatz J. Multicenter phase II study of rituximab and temozolamide in recurrent primary central nervous system lymphoma. Leuk Lymphoma. 2013;54:58–61.

    Article  CAS  PubMed  Google Scholar 

  134. Raizer JJ, Rademaker A, Evens AM, Rice L, Schwartz M, Chandler JP, Getch CC, Tellez C, Grimm SA. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. Cancer. 2012;118:3743–8.

    Article  CAS  PubMed  Google Scholar 

  135. Soussain C, Hoang-Xuan K, Taillandier L. Intensive chemotherapy followed by hematopoietic stem cell rescue for refractory and recurrent primary CNS and intraocular lymphoma.: Societe Française de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol. 2008;26:2512–8.

    Article  PubMed  Google Scholar 

  136. Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M, Bordonaro R, Ilariucci F, Faedi M, Corazzelli G, Manno P, Franceschi E, Pace A, Candela M, Abbadessa A, Stelitano C, Latte G, Ferreri AJ. Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer. 2007;96:864–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  137. Wong ET, Tishler R, Barron L, Wu JK. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer. 2004;101:139–45.

    Article  CAS  PubMed  Google Scholar 

  138. Osoba D, Brada M, Yung WK, Prados MD. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolamide. Eur J Cancer. 2000;36:1788–95.

    Article  CAS  PubMed  Google Scholar 

  139. Angelov L, Doolittle ND, Kraemer DF, Siegal T, Barnett GH, Peereboom DM, Stevens G, McGregor J, Jahnke K, Lacy CA, Hedrick NA, Shalom E, Ference S, Bell S, Sorenson L, Tyson RM, Haluska M, Neuwelt EA. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. L Clin Oncol. 2009;27:3503–9.

    Article  CAS  Google Scholar 

  140. Grommes C, Kaley TJ, Nolan C, et al. Phase I study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Abstract #2046. ASCO Annual Meeting, June 4, 2016; Chicago, IL.

  141. Rubenstein JL, Fraser E, Formaker P, Lee JCC, Chen N, Kock M, Cheung W, Wang X, Munster PN, Damato B. Phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide maintenance in recurrent CNS lymphoma.Am Soc Med Onc meeting, 2016, Abs 7502.

  142. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922–6.

    Article  CAS  PubMed  Google Scholar 

  143. Bernard S, Goldwirt L, Amorim S, Brice P, Briere J, de Kerviler E, Mourah S, Sauvageon H, Thieblemont C. Activitiy of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. Blood. 2015;126:1695–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. Wanquet A, Birsen R, Lemal R, Hunault M, Leblond V, Aurran-Schleinitz T. Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia. Blood. 2016;127:2356–8.

    Article  CAS  PubMed  Google Scholar 

  145. Dunleavy K, et al. 2015 ASH. Abstract 472 Dose-Adjusted TEDDI-R With Ibrutinib in Primary CNS Lymphoma: Phase I Study.

  146. Mason C, Savona S, Rini JN, Castillo JJ, Xu L, Hunter ZR, Treon SP, Allen SL. Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome. Br J Haematol. 2016;. doi:10.1111/bjh.14218.

    PubMed Central  Google Scholar 

  147. Gatalica Z, Vanderwalde AM, Rose I, Chen S, Reddy SK, Hamid O, Atkins MB. Distribution of PD-L1 expression in diverse cancer types: Experience with over 10,000 cases. J Clin Oncol. 34, 2016 (suppl; abstr 11548).

  148. Cooper FL, Riker JL. Malignant lymphoma of the uveal tract. Am J Ophtalmol. 1951;34:1153–8.

    Article  CAS  Google Scholar 

  149. Coupland SE, Chan CC, Smith J. Pathophysiology of retinal lymphoma. Ocular Immun Inflamm. 2009;17:227–37.

    Article  CAS  Google Scholar 

  150. Coupland SE, Heimann H, Bechrakis NE. Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features. Graefes Arch Clin Exp Ophtalmol. 2004;242:901–3.

    Article  Google Scholar 

  151. Fend F, Ferreri AJM, Coupland SE. How we diagnose and treat vitreoretinal lymphoma. Br J Haematol. 2016;173:680–92.

    Article  PubMed  Google Scholar 

  152. Reichstein D. Primary viteroretinal lymphoma: an update on pathogenesis, diagnosis and treatment. Curr Opin Ophthalmol. 2016;27:177–84.

    Article  PubMed  Google Scholar 

  153. Montesinos-rongen M, Brunn A, Bentink S, Basso K, Lim WK, Klapper W, Schaller C, Reifenberger G, Rubenstein J, Wiestler OD, Spang R, Dalla-Favera R, Siebert R. Deckert. Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center C cell. Leukemia. 2008;22:400–5.

    Article  CAS  PubMed  Google Scholar 

  154. Chan CC, Shen D, Hackett JJ, Buggage RR, Tuaillon N. Expression of chemokine receptors, CXCR4 and CXCR5 and chemokines, BLC and SDF-1 in the eyes of patients with primary intraocular lymphoma. Ophtalmology. 2003;110:421–6.

    Article  Google Scholar 

  155. Wallace DJ, Shen D, Reed GF, Miyanaga M, Mochizuki M, Sen HN, Dahr SS, Buggage RR, Nussenblatt RB, Chan CC. Detection of the bcl-2 t(14, 18) translocation nd proto-oncogen expression in primary intraocular lymphoma. Invest Ophtal Vis Sci. 2006;47:275–2756.

    Google Scholar 

  156. Montesinos-Rongen M, Zuhlke-Jenisch R, Gesk S, Martin-Subero JI, Schaller C, Van Roost D, Wiestler OD, Deckert M, Siebert R. Interphase cytogenetic analysis of lymphoma-associated chromosomal breakpoints in primary diffuse large B-cell lymphomas of the central nervous system. J Neuropathol Exper Neurol. 2002;61:926–33.

    Article  CAS  Google Scholar 

  157. Bonzheim I, Giese S, Deuter C, Susskind D, Zierhut M, Waizel M, Szurman P, Federmann B, Schmidt J, Quintanilla-Martinez L, Coupland SE, Bartz-Schmidt KU, Fend F. High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates. Blood. 2015;126:76–9.

    Article  CAS  PubMed  Google Scholar 

  158. Witmer MT. Primary vitreoretinal lymphoma: management of isolated ocular disease. Cancer Control. 2016;23:110–6.

    PubMed  Google Scholar 

  159. Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophtalmol. 1997;115:1152–6.

    Article  CAS  Google Scholar 

  160. de Smet MD. Management of non Hodgkin’s lymphoma with intravitreal methotrexate. Bull Soc Belge Ophtalmol. 2001;279:91–5.

    Google Scholar 

  161. Ma WL, Hou HA, Hsu YJ, Chen YK, Tang JL, Tsay W, Yeh PT, Yang CM, Lin CP, Tien HF. Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection. Ann Hematol. 2016;95(4):593–601. doi:10.1007/s00277-015-2582-x (Epub 2016 Jan 6).

    Article  CAS  PubMed  Google Scholar 

  162. Singh AD, Peerebom DM. Intraocular rituximab. Eye. 2007;21:1453–4.

    Article  CAS  PubMed  Google Scholar 

  163. Ohguro N, Hashida N, Tano Y. Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma. Arch Ophtalmol. 2008;126:1002–3.

    Article  CAS  Google Scholar 

  164. Larkin KL, Saboo US, Comer GM, Forooghian F, Mackensen F, Merrill P, Sen HN, Singh A, Essex RW, Lake S, Lim LL, Vasconcelos-Santos DV, Foster CS, Wilson DJ, Smith JR. Use of intravitreal rituximab for treatment of vitreoretinal lymphoma Br J Ophthalmol. 2014;98:99–103.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey

    Semra Paydas

Authors
  1. Semra Paydas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Semra Paydas.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Paydas, S. Primary central nervous system lymphoma: essential points in diagnosis and management. Med Oncol 34, 61 (2017). https://doi.org/10.1007/s12032-017-0920-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-017-0920-7

Keywords

Search

Navigation